FirstWord

Brainomix's 360 E-lung software found that patients treated with taladegib had "significant positive differences" in lung volume, overall interstitial lung disease burden and total fibrosis extent.

Deucrictibant XR, a bradykinin B2 antagonist, met the primary and all secondary endpoints in Phase III CHAPTER-3 trial.

The bispecific T-cell engager, in combination with AstraZeneca's Imfinzi, improved overall survival, progression-free survival and overall response rate compared with Imfinzi alone.

"The goal is not a better GLP-1; it is to open a different area of biology that could work on its own or alongside incretins," CEO Alex Aravanis told FirstWord.

Results showed that the GPRC5D-directed CAR-T cell therapy arlocabtagene autoleucel demonstrating a statistically significant overall response rate in patients with quadruple-class exposed relapsed and refractory multiple myeloma.

BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological ControlWith Up to 18 Months Fol...

Rapid, deep, and durable pharmacodynamic activity demonstrated across key Type 2 inflammatory biomarkers, including pSTAT6, TARC, eosinophils, and IgE Extended half-life and 85% subcutaneous bioavaila...

Pa-positive NCFB patients experienced a significant reduction in annualised exacerbation rate from 3.4 in the prior 12 months to 1.2 on RESP-X treatmentOnly one exacerbation meeting the Hill/EMBARC cr...

- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort -- Dyne also intends to p...

First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disordersNew SPRAVATO ® analyses and schizophrenia research emphasize a ...